⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIVW News
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
globenewswire.com
ROIVW
ABUS
ROIV
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
globenewswire.com
ROIV
ROIVW
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
globenewswire.com
ROIV
ROIVW
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
globenewswire.com
ROIV
ROIVW